New Insight Into Hyperthermic Intraperitoneal Chemotherapy
Authors:
- Kuno LehmannKLKuno Lehmann
- Lotta von BoehmerLBLotta von Boehmer
- Rolf GrafRGRolf Graf
- Pierre-Alain ClavienPCPierre-Alain Clavien
- 1 November 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 256 (5) , 730-738
Abstract
Background: The aim of hyperthermic intraperitoneal chemotherapy (HIPEC) is to eradicate microscopic residual tumor after radical surgical tumor excision in patients with peritoneal carcinomatosis. The common use of antineoplastic agents such as mitomycin C, doxorubicin, or oxaliplatin with hyperthermia fails to eradicate tumors in a significant subset of patients, and alternative approaches to target chemoresistant cells are needed. The induction of reactive oxygen species (ROS) by inhibiting the critical detoxification enzyme superoxide dismutase (SOD) during hyperthermia is an appealing approach to induce death of residual cancer cells. Methods: Human and murine colon cancer cell lines were subjected to mild hyperthermia (40–42°C), and treated with chemotherapy, similar to clinical protocols. ROS were induced by the SOD inhibitor diethyldithiocarbamate (DDC), a metabolite of the drug disulfiram. In mice, peritoneal carcinomatosis use C57Bl/6 was induced in C57Bl/6 by intraperitoneal injection of syngenic tumor cells (MC38). Results: Hyperthermia alone failed to kill cells but induced intracellular ROS and activated protective mechanisms. Chemotherapy conferred inconsistent cytotoxicity depending on the cell line and dose. In contrast, induction of ROS by DDC consistently activated apoptotic pathways, with increased cell death in combination with mild hyperthermia. In vivo, combined treatment with DDC and hyperthermia significantly delayed tumor progression in tumor-bearing mice. In addition, hyperthermic combined treatment with chemotherapy and DDC significantly improved animal survival compared with chemotherapy alone. Conclusions: Addition of DDC improves the efficacy of existing HIPEC protocols in a safe way and may open the door to a more effective, multimodal HIPEC.Keywords
This publication has 34 references indexed in Scilit:
- Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841Journal of Clinical Oncology, 2012
- Loss of sphingosine kinase‐1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin‐induced DNA damageBritish Journal of Pharmacology, 2010
- Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French StudyJournal of Clinical Oncology, 2010
- Is resistance useless? Multidrug resistance and collateral sensitivityTrends in Pharmacological Sciences, 2009
- Thermal Sensitization Using Induced Oxidative Stress Decreases Tumor Growth in an In Vivo Model of Hyperthermic Intraperitoneal PerfusionAnnals of Surgical Oncology, 2009
- Slow proliferation as a biological feature of colorectal cancer metastasisBritish Journal of Cancer, 2009
- Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal OriginJournal of Clinical Oncology, 2009
- Results of Systematic Second-Look Surgery in Patients at High Risk of Developing Colorectal Peritoneal CarcinomatosisAnnals of Surgery, 2008
- Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunityGut, 2006
- Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermiaThe Lancet Oncology, 2004